Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06282458 | Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt | PHASE2 | COMPLETED | 168 | — | — | Apr 29, 2024 | Aug 22, 2025 | Sep 17, 2025 | 14 | United States |
To determine the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists (percent change in total lean mass) at 112 days.
| Arm | Type | Description |
|---|---|---|
| Semaglutide and Enobosarm 3 mg QD by mouth (E3G) daily | EXPERIMENTAL | Approximately 50 subjects will be dosed with semaglutide injected once-weekly and enobosarm 3 mg QD by mouth (E3G) daily for approximately 112 days. Semaglutide dose escalation will occur as follows: Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg From Day 112 to Day 196, patients will continue to receive 3 mg enobosarm QD by mouth and will discontinue the semaglutide. |
| Semaglutide and Enobosarm 6 mg QD by mouth (E6G) daily | EXPERIMENTAL | Approximately 50 subjects will be dosed with semaglutide injected once-weekly and enobosarm 6 mg QD by mouth (E3G) daily for approximately 112 days. Semaglutide dose escalation will occur as follows: Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg From Day 112 to Day 196, patients will continue to receive 6 mg enobosarm QD by mouth and will discontinue the semaglutide. |
| GLP-1 receptor agonist and Placebo QD by mouth (PG) daily | PLACEBO_COMPARATOR | Approximately 50 subjects will be dosed with semaglutide injected once-weekly and placebo QD by mouth (PG) daily for approximately 112 days. Semaglutide dose escalation will occur as follows: Weeks 1 through 4 - 0.25mg Weeks 5 through 8 - 0.5mg Weeks 9 through 12 - 1mg Weeks 13 through 16 - 1.7mg From Day 112 to Day 196, patients will continue to receive placebo QD by mouth (PG) and will discontinue the semaglutide. |
| Name | Type | Description |
|---|---|---|
| Enobosarm | DRUG | Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function. |
| Semaglutide | DRUG | Semaglutide for Chronic Weight Management |
Inclusion Criteria: Subjects accepted for this study must: 1. Provide informed consent from the subject or the subject's legally authorized representative 2. Be able to communicate effectively with the study personnel 3. Aged ≥60 years 4. For Female Subjects * Menopausal status * Be post...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Abbott Laboratories | ABT | 1 | — | Undisclosed |
| CytoSorbents Corporation | CTSO | 1 | — | Undisclosed |